Aperture Bio & NuView Life Sciences Sign Definitive Agreement to Investigate Expanded Indications for the RAPID-BTM to Include the NV-VPAC1TM Developed for the Detection of Prostate and other Urogenital Cancers

(Dallas, TX/Salt Lake City, UT) – In a joint press release, Aperture Bio and NuView Life Sciences have entered into an agreement to begin collaborative investigational studies to assess NuView’s proprietary NV-VPAC1(TM) urogenital cancer test utilizing Aperture Bio’s RAPID-B(TM) proprietary screening platform.

Aperture Bio has developed a proprietary diagnostic platform, the RAPID-BTM, designed for rapid and accurate detection of bacterial infections found in both urine and blood specimens. The system utilizes highly customized and robotic flow cytometric instrumentation that can rapidly identify and enumerate targeted cellular material in bodily fluids, i.e. bacteria and white blood cells.

The RAPID-B(TM) was developed in conjunction with Aperture’s proprietary empiriSTAT and m.i.c.STAT series of tests, which include rapid Antibiotic Predictive Profiling (APP) for samples screening positive. In pre-FDA submission studies, the empiriSTAT-UTI, for detection of uncomplicated urinary tract infections, proved highly accurate achieving 98% sensitivity and 88% specificity in minutes compared to traditional cultures taking 18-24 hours. Overall accuracy for the APP portion of the test is approximately 95% compared to traditional AST.

According to its lead developer, CMO and co-founder, Dr. Matthew Gombrich, “The RAPID-B was developed around our empiriSTAT tests for precise identification and enumeration of viable bacteria cells. Our primary goal was to reduce the need for empirical antibiotic prescribing thus reducing the pressures on antibiotic resistance, improving patient outcomes and lowering costs.

Applying quantitative microbiology to a robust, high throughput, automated platform, could outperform today’s standard methodologies and greatly improve how infections, or other disease diagnostics are performed. Although our first validation studies focused on bacteria and white blood cells, we believe or proprietary platform and algorithoms could perform equally as well identifying other cellular types like voided urine prostate cancer cells or bladder cancer cells detected by the NuView biomarker. Automating these applications could offer an improved method for annual or semi-annual screening protocols.”

NuView has licensed from Thomas Jefferson University a proprietary, in vitro test, the NV-VPAC1(TM),. The test, utilizing proprietary peptide analogs invented by Dr. Mathew Thakur and Dr. Leonard Gomella will identify cells overexpressing the VPAC1 protein associated with malignant transformation. Initial application will focus on identifying early-stage prostate cancer in voided urine. The company believes that with further testing it could identify other known cancers associated with urogenital system, i.e. uterine, renal and bladder cancer.

Current methodologies to asses the NV-VPAC1(TM) are performed using florescence microscopy on a test-by-test basis. This process, although effective, can be cumbersome and time consuming for commercial and institutional labs serving large patient populations and managing high test volumes. As with any test inturpited by an individual, there is the potential of a ‘margin of human subjectivity’ possible from one reader to the next. Automation of the NuView test could improve throughput capabilities, enhancing clinical and commercial utilization, and possibly reduce or remove any variances in interpretation. Incorporating a high throughput, accurate platform into its testing protocols could make this potentially life saving test available to more patients throughout the world.

The companies believe that combining both technologies through a collaborative scientific effort could provide significant increased market and clinical value for both companies. These expanded indications could provide significant value to both companies and the communities at large. Providing an institutional or commercial laboratory the diagnostic tools to rapidly and accurately identify two of the most common and deadly world health risks, cancer and bacterial infections, could redefine how both are identified and treated.

In a joint statement from David Potenza, President of Aperture Bio and Paul Crowe, Founder and CEO at NuView Life Sciences “The potential for both companies to come together scientifically and offer the market a fast and highly accurate single platform to assess both patients at risk of cancer and bacterial infection could dramatically improve diagnostic laboratory efficiency and improve patient outcomes throughout the world.”

Both companies are currently seeking investors and for more information please contact the companies directly.

###

David Potenza
President
20 Winter Sport LN
Williston, VT 05495

dpotenza@aperturebio.com
Phone 214-707-8710

About Aperture Bio – www.Aperturebio.com is a would health diagnostic company dedicated to helping combat the clinical and economic impact of bacterial infections and the over or misuse of antibiotics contributing to antibiotic resistance.

NuView Life Sciences - www.NuViewLifeSciences.com is focused on creating precision cancer diagnostics and therapeutics to improve patient outcomes while reducing healthcare costs through the development and clinical application of its exclusive peptide analog technology, NV-VPAC1(TM).

This release was published on openPR.